Cogstate Ltd · ASX:CGS
Cogstate — Non-Deal Roadshow (March 2009)
15 slides from Cogstate's roadshow presentation, Mar 3, 2009
Slide 1: Investor Roadshow March 2009
For personal use only Investor Roadshow March 2009 www.cogstate.com
Slide 2: Overview
Overview CogState (ASX: CGS) is a health services and equipment company that provides cognition testing technology to pharmaceutical For personal use only companies undertaking clinical trials Share price $0.22 Market cap (as at 02/03/09) $14.4m Cash (as at 31/12/08) $2.8m (excluding debtors $1.2m)
Slide 3: CogState's core business model - explained
CogState’s core business model - explained • Provides cognition testing to the global pharmaceutical industry within the For personal use only clinical trial process • Cognition testing used in many clinical trials for drugs designed to work on central nervous system diseases and disorders – looking
Slide 4: Market Size – available figures
CogState’s core business model - explained Market Size – available figures For personal use only • 820 drug trials currently registered with the National Institutes of Health in the USA for CNS diseases and disorders: Disease Phase I Phase II Phase Phase IV III Alzheimer’s Disease 29 36 21 22 Schizo
Slide 5: H1 Results
H1 Results Summary of financial results for the half year ended 31 Dec 2008: For personal use only • Net profit after tax of $1.29 million • Revenue up 135% to $3.92 million (2007: $1.67 million) – Revenue for the 2008 calendar year exceeded $6 million • Value of sales contracts signed up 75% to $4.
Slide 6: Sales Revenue, by Half Year
For personal use only Sales Revenue, by Half Year www.cogstate.com
Slide 7: Operating Cash Flow
For personal use only Operating Cash Flow www.cogstate.com
Slide 8: December - Summary Balance Sheet
31 December - Summary Balance Sheet Includes impact of capital raising from Rights Issue and Private Placement For personal use only 30 June 08 31 Dec 08 Movement Cash and cash 1,048,207 2,776,674 1,728,467 investments Trade debtors 612,778 1,198,303 585,525 Other assets 236,971 214,875 (22,096) Fix
Slide 9: Profit Guidance
Profit Guidance The following guidance is provided in respect of the half year ending 30 June 2009: For personal use only • Contracts already in place will generate $3.4 million revenue in future periods, of which $2 million is expected to be recognised before 30 June 2009 • Revenue for the half for
Slide 10: Why CogState is growing so rapidly
Why CogState is growing so rapidly • Key CogState staff (Dr. Paul Maruff, Dr. John Harrison, Dr David Darby and Prof. Peter Snyder) provide a high level of scientific expertise in respect of measuring For personal use only cognitive change in clinical trials • The scientific expertise is combined wi
Slide 11: Is the growth sustainable?
Is the growth sustainable? • Increased use of CogState in phase 2 & 3 clinical trials – Larger contracts over longer time period providing greater certainty of For personal use only contracted revenue from future periods • Cognition continues to be an area of focus in many indications, but particula
Slide 12: Market dynamics & the CogState advantage
Market dynamics & the CogState advantage • CogState provides rapid computerised testing batteries - < 15 mins For personal use only • Datapoint® – real time information etc to clients • Top Down business model – prove capability for new customers via Phase 1 trials – allows for other Phase 1, and ne
Slide 13: United BioSource Corp. (UBC) Partnership
United BioSource Corp. (UBC) Partnership • Original agreement for 12 months, not renewed For personal use only • CogState well positioned to be able to grow operational capabilities and manage large studies – Additional resources in both USA & UK • Focus on technology advancement to more efficiently
Slide 14: Positive outlook
Positive outlook • Profit guidance provided for FY 2009 For personal use only – $1.50 - $1.75 million NPAT • Contracts already in place will generate $3.4 million revenue in future periods • Defensive outlook given volatile economic conditions – Customers are big pharma companies – Provided pharma c
Slide 15: For personal use only
For personal use only Brad O’Connor Chief Executive Officer CogState Ph: 03 9664 1300 boconnor@cogstate.com www.cogstate.com